Clinical study of haploidentical hematopoietic stem cell transplantation as a treatment of hematopoietic malignancies
WANG Zhi-ming
WANG Lin
CHEN Xiao-xia
LUO Xian-sheng
HE Li-li
HUANG Zi-ying
FU Rong-xiang
WANG Yun-ying
LI Li-qiong
TAN Lion
XU Dan-dan
LI Xing
Abstract：Objective To study the effect of haploidentical hematopoietic stem cell transplantation as a treatment of hematopoietic malignancies. Methods We used cytosine arabinoside ( Ara-c) , busulphan ( Bu) , cyclophosphamide (CTX) and methyl ccnu (MeCCNU) as preconditioning of patients and then we used cyclophosphamide(CTX), rhG-CSF, cyclosporine A ( CSA ), mycophenolate mofetil ( MMF), the anti-thymocyte globulin ( ATG) , IL-11 and methotrexate( MTX) as prophylaxis of acute graft versus host diseases to treat 8 cases of hematopoietic malignancies. Results All patients achieved complete engraftment. The median times of neutrophil recovery > 1.0 ×109/L were 16. 3 (12～20)days after transplantation. The incidence of grade Ⅲ～Ⅳ aGVHD was 12.5%. All patients survived disease-free with a median follow-up of 28. 8 (4～65) months. Conclusions Haploidentical hematopoietic stem cell transplantation is a safe and effective treatment for hematopoietic malignancies, with Ara-c, Bu, CTX, MeCCNU as preconditioning and CTX, rhG-CSF, CSA, MMF, ATG, IL-11 and MTX as prophylaxis of aGVHD.
Keywords：Hematologic neoplasmsHematopoietic stem cell transplantationHaploidy
Publication Date：2010-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)